National Institute on Drug Abuse; Notice of Closed Meeting, 75055-75056 [2022-26611]
Download as PDF
Federal Register / Vol. 87, No. 234 / Wednesday, December 7, 2022 / Notices
As part of the process of issuing this
final guidance, FDA has also taken into
consideration the Citizen Petition filed
on behalf of Americans for Homeopathy
Choice received by FDA on June 5,
2020, the reasoning set forth in FDA’s
response to that Petition, and the
references cited therein. And as part of
the process of issuing FDA’s response to
that Petition, FDA has taken into
consideration the comments received on
the original and revised draft guidances,
the reasoning set forth in this final
guidance, and the references cited
therein.
This final guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115). It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
II. Paperwork Reduction Act of 1995
This guidance contains no collection
of information. Therefore, clearance by
the Office of Management and Budget
under the Paperwork Reduction Act of
1995 is not required.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/default.htm,
https://www.fda.gov/vaccines-bloodbiologics/guidance-complianceregulatory-information-biologics/
biologics-guidances, https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents, or
https://www.regulations.gov.
Dated: December 1, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–26567 Filed 12–6–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Advisory Committee on
Children and Disasters; Meeting
Office of the Assistant
Secretary for Strategic Preparedness and
Response (ASPR), Department of Health
and Human Services (HHS).
ACTION: Notice.
ddrumheller on DSK6VXHR33PROD with NOTICES
AGENCY:
The National Advisory
Committee on Children and Disasters
(NACCD or the Committee) is required
by section 2811A of the PHS Act, as
amended by the Pandemic and All
SUMMARY:
VerDate Sep<11>2014
19:54 Dec 06, 2022
Jkt 259001
Hazards Preparedness and Advancing
Innovation Act (PAHPAIA) and
governed by the provisions of the
Federal Advisory Committee Act
(FACA). The NACCD shall evaluate
issues and programs and provide
findings, advice, and recommendations
to the Secretary of HHS and ASPR to
support and enhance all-hazards public
health and medical preparedness,
response, and recovery aimed at
meeting the unique needs of children
and their families across the entire
spectrum of their wellbeing. The
Secretary of HHS has formally delegated
authority to operate the NACCD to
ASPR.
DATES: The NACCD will conduct a
public meeting (virtual) on January 18,
2023 to discuss, finalize and vote on an
initial set of recommendations to the
HHS Secretary and ASPR regarding
challenges, opportunities, and priorities
for national public health and medical
preparedness, response and recovery,
specific to the needs of children and
their families in disasters. A more
detailed agenda and meeting registration
link will be available on the NACCD
meeting website https://www.phe.gov/
Preparedness/legal/boards/naccd/
Pages/default.aspx.
ADDRESSES: Members of the public may
attend the meeting via a toll-free phone
number or Zoom teleconference, which
requires pre-registration. The meeting
link to pre-register will be posted on
https://www.phe.gov/Preparedness/
legal/boards/naccd/Pages/default.aspx.
Members of the public may provide
written comments or submit questions
for consideration to the NACCD at any
time via email to NACCD@hhs.gov.
Members of the public are also
encouraged to provide comments after
the meeting.
FOR FURTHER INFORMATION CONTACT:
Zhoowan Jackson, NACCD Designated
Federal Officer, Office of the Assistant
Secretary for Strategic Preparedness and
Response (ASPR), Department of Health
and Human Services (HHS),
Washington, DC; 202–205–4217,
NACCD@hhs.gov.
SUPPLEMENTARY INFORMATION: The
NACCD invites those who are involved
in or represent a relevant industry,
academia, health profession, health care
consumer organization, or state, Tribal,
territorial, or local government to
request up to four minutes to address
the committee live via Zoom. Requests
to provide remarks to the NACCD
during the public meeting must be sent
to NACCD@hhs.gov at least 15 days
prior to the meeting along with a brief
description of the topic. We would
specifically like to request inputs from
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
75055
the public on disaster behavioral health,
COVID–19 pandemic lessons learned
and other challenges, opportunities, and
strategic priorities for national public
health and medical preparedness,
response and recovery specific to the
needs of children and their families in
disasters
Dawn O’Connell,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2022–26561 Filed 12–6–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Production of Cannabis and Related
Materials for Research.
Date: January 6, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
M.B.B.S., Scientific Review Officer, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443–
4577, nayarp2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
E:\FR\FM\07DEN1.SGM
07DEN1
75056
Federal Register / Vol. 87, No. 234 / Wednesday, December 7, 2022 / Notices
Dated: December 2, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–26611 Filed 12–6–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information on Proposed
Simplified Review Framework for NIH
Research Project Grant Applications
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Request for information.
The purpose of this Request
for Information (RFI) is to solicit public
input on a proposed revised framework
for evaluating and scoring peer review
criteria for National Institutes of Health
(NIH) research project grant (RPG)
applications. NIH is proposing a revised
simplified framework that will
reorganize five major regulatory criteria
under three scored categories and
reduce the number of non-score driving
review considerations that reviewers
evaluate in judging the scientific merit
of RPG applications. The proposed
changes pertain to those RPGs with
standard review criteria. All the factors
required by regulation will continue to
be evaluated. NIH is not proposing to
revise the regulatory criteria. Rather,
NIH is proposing to revise its policy of
how peer reviewers score the criteria,
and how NIH organizes the criteria for
review purposes. NIH believes that
these changes will allow peer reviewers
to refocus on the critical task of judging
scientific merit and will improve those
judgements by reducing bias.
DATES: The RFI is open for public
comment for a period of 90 days.
Comments must be received by 11:59:59
p.m. (ET) on March 10, 2023, to ensure
consideration.
ADDRESSES: Submissions can be sent
electronically to https://rfi.grants.
nih.gov/?s=638509b54
09baa49f803e572). NIH is specifically
requesting public comment on the
Proposed Revised Simplified Review
Framework, a proposed revised
framework for evaluating and scoring
peer review criteria for NIH research
project grant applications, described
above. Response to this RFI is voluntary.
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Office
of Extramural Research, Dr. Kristin
ddrumheller on DSK6VXHR33PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:54 Dec 06, 2022
Jkt 259001
Kramer, Phone number (301) 437–0911,
Email simplifiedreview@nih.gov.
SUPPLEMENTARY INFORMATION:
Current Process
The first stage of NIH peer review
serves to provide expert advice to NIH
on the scientific and technical merit of
grant applications. The NIH peer review
regulations at 42 CFR part 52h.8 state
that for research project grant
applications, the scientific peer review
group shall assess the overall impact
that the project could have on the
research field involved, taking into
account, among other pertinent factors:
(a) The significance of the goals of the
proposed research, from a scientific or
technical standpoint;
(b) Approach: The adequacy of the
approach and methodology proposed to
carry out the research;
(c) Innovation: The innovativeness
and originality of the proposed research;
(d) Investigator(s): The qualifications
and experience of the principal
investigator and proposed staff;
(e) Environment: The scientific
environment and reasonable availability
of resources necessary to the research;
(f) The adequacy of plans to include
both genders, minorities, children and
special populations as appropriate for
the scientific goals of the research;
(g) The reasonableness of the
proposed budget and duration in
relation to the proposed research; and
(h) The adequacy of the proposed
protection for humans, animals, and the
environment, to the extent they may be
adversely affected by the project
proposed in the application.
By NIH policy at: https://
grants.nih.gov/grants/policy/nihgps/
HTML5/section_2/2.4.1_initial_
review.htm# Addition, peer reviewers
are currently also required to evaluate
Biohazards, Resubmissions, Foreign
Organizations, Select Agents, Resource
Sharing Plans, and Authentication of
Key Biological and/or Chemical
Resources. NIH currently gives the first
five of the regulatory factors the
following categorical labels:
Significance, Approach, Innovation,
Investigator(s), and Environment.
The NIH peer review regulation does
not address scoring. Scoring of all
regulatory factors is determined by NIH
policy. Currently, peer reviewers
provide an Overall Impact Score (scored
1–9) that reflects the overall scientific
and technical merit of the application
and individual criterion scores for
Significance, Investigators, Innovation,
Approach, and Environment. The
remaining factors, Protections for
Human Subjects, Inclusion, Vertebrate
Animals, Biohazards, Resubmission,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Renewal, and Revision are evaluated
and factored into the Overall Impact
Score; however, they are not given
individual scores. When reviewers
judge any of these to be unacceptable,
they are asked to provide justification
for that assessment. Beyond these
factors, reviewers are asked to assess the
following additional review
considerations, but these considerations
are not considered when reviewers
determine an Overall Impact Score:
Applications from Foreign
Organizations, Select Agents, Resource
Sharing Plans, Authentication of Key
Biological and/or Chemical Resources,
Budget & Period of Support.
Proposal Development
NIH gathered input from many
sources in forming this proposal.
Unsolicited comments over a period of
years, reflecting sustained concerns
from reviewers and applicants regarding
complexity of review criteria,
administrative load, and potential biases
led the Center for Scientific Review
(CSR) to form a working group to the
CSR Advisory Council. To inform that
group, CSR published a Review Matters
blog at: https://www.csr.nih.gov/
reviewmatters/2020/02/27/seeking-yourinput-on-simplifying-review-criteria/
which was cross-posted on the Office of
Extramural Research blog, Open Mike
at: https://nexus.od.nih.gov/all/2020/
02/27/seeking-your-input-onsimplifying-review-criteria/. The blog
received more than 9,000 views by
unique individuals and over 400
comments. The working group
presented interim recommendations at:
https://public.csr.nih.gov/sites/default/
files/2019-10/Review_criteria_wg_
CSRAC_interim_report_7April2020.pdf
to the CSR Advisory Council, which
adopted the recommendations, at public
CSR Advisory Council meetings (March
2020 video https://videocast.nih.gov/
summary.asp?live=35649&
bhcp=1&start=4307, slides https://
public.csr.nih.gov/sites/default/files/
presentations/200330/Simplifying_
Review_Criteria_Workgroup_Interim_
Rpt_final.pdf; March 2021 video https://
videocast.nih.gov/
watch=41574&start=4816, slides https://
public.csr.nih.gov/sites//files/2021-04/
Simplifying_Review_Criteria_29_March_
2021.pdf). Final recommendations from
the CSR Advisory Council (report
https://public.csr.nih.gov/sitest/files/
2021-04/Recommendations_of_the_
CSRAC_Working_Group_on_
Simplifying_Review-non-CT_and_
CT.pdf) were considered by the CSR
Director, as well as major internal NIH
extramural-focused committees that
included leadership from across NIH
E:\FR\FM\07DEN1.SGM
07DEN1
Agencies
[Federal Register Volume 87, Number 234 (Wednesday, December 7, 2022)]
[Notices]
[Pages 75055-75056]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26611]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Production of Cannabis and Related Materials for
Research.
Date: January 6, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., M.B.B.S., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 443-4577, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
[[Page 75056]]
Dated: December 2, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-26611 Filed 12-6-22; 8:45 am]
BILLING CODE 4140-01-P